Author(s): Chaudhry MA, Pappy R, Hennebry TA
Abstract Share this page
Abstract OBJECTIVES: The Trellis thrombectomy system (Covidien) is one of the newer devices that incorporates isolated pharmacomechanical thrombectomy and thrombolysis (PMT) for treatment of deep venous thrombosis (DVT). We conducted a retrospective review of patients with upper- and lower-extremity DVT managed with the Trellis thrombectomy system at our center. METHODS: All patients with symptomatic DVT who presented to our center between April 2010 and April 2011 who underwent PMT by the Trellis device were included in this retrospective review. RESULTS: Twenty-eight patients (mean age, 46.4 ± 21.2 years) presented with symptoms with a mean duration of 1.3 ± 1.8 months. Eighty-six percent had 100\% occlusion on admission, while 14.3\% had 70\%-90\% stenosis. The mean lytic dose used was tPA 20.7 ± 12 mg. The mean Trellis treatment time was 25.1 ± 11.5 minutes. Grade 3 lysis was achieved in 23 of 28 patients (85.8\%), while grade 2 lysis was achieved in 14.2\%. Mean total hospital stay was 2.6 ± 2.7 days. Postprocedure symptom resolution was 100\%, and there was no reocclusion in 78.6\% of patients at 1 year. At 12 months, the patency rate (primary or secondary) was 80\% as determined by Doppler ultrasound. CONCLUSIONS: In patients with DVT involving the ilio-femoral and the upper-extremity vessels, the use of the Trellis device was associated with a high technical success rate as well as a satisfactory 12-month patency rate. Moreover, this strategy was associated with reduced lytic dose, shorter treatment time and hospital stay, and no bleeding complications.
This article was published in J Invasive Cardiol
and referenced in Internal Medicine: Open Access